Leonard S. Schleifer Salary and Compensation - REGENERON PHARMACEUTICALS, INC. CEO Pay 2025

In fiscal year 2025, Leonard S. Schleifer, M.D., Ph.D. Board co-Chair, President and Chief Executive Officer of REGENERON PHARMACEUTICALS, INC. (REGN), received total compensation of $7.3 million.

Leonard S. Schleifer's compensation breakdown includes: base salary of $2.0 million, non-equity incentive compensation of $3.7 million, and other compensation of $1.6 million.

Compared to fiscal year 2024, Leonard S. Schleifer's total compensation increased 7% from $6.8 million to $7.3 million.

REGENERON PHARMACEUTICALS, INC. (REGN) Executive Pay 2025

REGENERON PHARMACEUTICALS, INC.'s top 6 named executive officers received combined total compensation of $45.9 million in fiscal year 2025.

The named executive officers disclosed in REGENERON PHARMACEUTICALS, INC.'s 2025 proxy statement are:Leonard S. Schleifer (M.D., Ph.D. Board co-Chair, President and Chief Executive Officer) with total compensation of $7.3 million, Daniel P. Van Plew (Executive Vice President and General Manager Industrial Operations and Product Supply) with total compensation of $8.8 million, Andrew J. Murphy (Ph.D. Executive Vice President, Co-Chief Scientific Officer) with total compensation of $8.5 million, Joseph J. La Rosa (Executive Vice President General Counsel and Secretary) with total compensation of $7.5 million, Christopher Fenimore (Executive Vice President Finance and Chief Financial Officer) with total compensation of $7.0 million, and George D. Yancopoulos (M.D., Ph.D. Board co-Chair, President and Chief Scientific Officer) with total compensation of $6.9 million.